Inhibitors of the PD1/PDL1 immune checkpoint have revolutionized cancer treatment. Here, we discuss the differing development strategies of global and Chinese biopharma companies for PD1/PDL1-targeted agents by comparing the landscapes for approvals and pivotal trials.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Acknowledgements
The authors gratefully acknowledge Xinwen Luo (Pharmcube) for data collection.
Competing Interests
Y.Q. and S.Y. are employees at Pharmcube. The other authors declare no competing interests.